Related Experiment Video

Updated: Aug 17, 2026

Improving IV Insulin Administration in a Community Hospital
12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

Continuous subcutaneous insulin infusion in type 1 diabetic Saudi children. A comparison with conventional insulin

Bassam S Bin-Abbas1, Nadia A Sakati, Hussein Raef

  • 1Section of Pediatric Endocrinology, Department of Pediatrics, MBC 58, King Faisal Specialist Hospital and Research Centre, PO Box 3354, Riyadh 11211, Kingdom of Saudi Arabia. benabbas@kfshrc.edu.sa

Saudi Medical Journal
|June 29, 2005
PubMed

Insights

Continuous subcutaneous insulin infusion (CSII) therapy significantly improved glycemic control in Saudi children with type 1 diabetes mellitus (T1DM). CSII reduced hypoglycemia and diabetic ketoacidosis (DKA) events compared to conventional insulin therapy.

Area of Science:

  • Pediatric Endocrinology
  • Metabolic Disorders
  • Diabetes Management

Background:

  • Type 1 diabetes mellitus (T1DM) requires intensive management to prevent complications.
  • Conventional insulin (CI) therapy involves multiple daily injections.
  • Continuous subcutaneous insulin infusion (CSII) offers an alternative delivery method.

Purpose of the Study:

  • To evaluate the efficacy and effectiveness of CSII versus CI in Saudi children with T1DM.
  • To compare glycemic control and complication rates between CSII and CI therapies.

Main Methods:

  • 14 Saudi children with T1DM transitioned from CI to CSII therapy.
  • Patients received training on carbohydrate counting and basal-bolus insulin delivery via pump.
  • Follow-up occurred at a specialized diabetes clinic over a mean of 10 months.

Main Results:

  • CSII therapy led to a significant reduction in hemoglobin A1c and mean blood glucose levels.
  • Total insulin requirements decreased with CSII.
  • Frequency of hypoglycemic episodes and diabetic ketoacidosis (DKA) events were significantly reduced.

Conclusions:

  • CSII therapy demonstrates improved glycemic control in Saudi children with T1DM.
  • CSII therapy is associated with a lower incidence of hypoglycemia and DKA events.
  • Further long-term studies are recommended to validate these findings.
Abstract

More Related Videos

Measuring Relative Insulin Secretion using a Co-Secreted Luciferase Surrogate05:58

Measuring Relative Insulin Secretion using a Co-Secreted Luciferase Surrogate

Published on: June 25, 2019

Related Concept Videos

Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Insulin Formulations: Types and Delivery01:27

Insulin Formulations: Types and Delivery

Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into rapid-acting...
Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type I Diabetes I: Introduction01:12

Type I Diabetes I: Introduction

Type 1 diabetes mellitus is a chronic metabolic disorder characterized by an absolute deficiency of insulin resulting from the autoimmune destruction of pancreatic β-cells. Although it can occur at any age, it is most commonly diagnosed in childhood, adolescence, or early adulthood. The loss of insulin production impairs cellular glucose uptake, resulting in persistent hyperglycemia and necessitating lifelong insulin therapy.Autoimmune Destruction of β-CellsThe hallmark of type 1 diabetes is an...
Diabetic Ketoacidosis l: Introduction01:25

Diabetic Ketoacidosis l: Introduction

DefinitionDiabetic ketoacidosis (DKA) is an acute, life-threatening complication of diabetes mellitus, characterized by a triad of hyperglycemia (blood glucose >250 mg/dL), ketonemia or ketonuria, and metabolic acidosis (arterial pH <7.30 and serum bicarbonate <18 mEq/L). It results from insulin deficiency combined with elevated levels of counterregulatory hormones—glucagon, catecholamines, cortisol, and growth hormone—leading to increased lipolysis, hepatic ketone production, and...
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...